

NF Clinical Pipeline: Interventional Drug Therapies

The data provided in this section is for information only and does not constitute medical advice, nor does it constitute an endorsement of any of the clinical activities listed. The trials listed below are compiled from U.S. and European information sources.

	TARGET	Agent	Phase 0	Phase 1	Phase 1/2	Phase 2	Phase 3	Patients
LG Glioma								
(EU Trial: NO, IE)	Chemotherapy mTOR Anti-angiog, pro-Apopt, anti-Infl, Immuno-Modulatory MEK	Vincristin, Carboplatin, Etoposide Everolimus (RAD001) Lenalidomide Selumetinib (AZD-6244)	█	█	█	█		
Plexiform								
Adults Children, Young Adults (EU Trial: ES) (EU Trial: IT)	Antiprolif, Antiangiogenic Antiprolif, Antiangiogenic Tyr-Kinase Tyr-Kinase mTOR Tyr-Kinase MEK Tyr-Kinase MEK MEK	PEG-interferon α-2b PEG-interferon α-2b Imatinib Imatinib Everolimus (RAD001) Sutent/Sunitinib MEK162 Cabozantinib Trametinib (GSK-212) Selumetinib (AZD-6244)	█	█	█	█		
MPNST								
	Hedgehog + γ-secretase Tyr-Kinase + Chemo Tyr-Kinase + Chemo mTOR + HSP90	Vismodegib, RO4929097 Pazopanib, Gemcitabine, Docetaxel Pazopanib, doxorubicin, ifosfamide Sirolimus, ganetespib	█	█	█	█		
Others								
Autism (EU Trial: UK) Bone Issues Learning Dermal	HMG-CoA Reductase Vitamin D HMG-CoA Reductase Photosensitizer (PhotoDynamic Therapy)	Simvastatin Cholecalciferol (Vit.D) Lovastatin Levulan	█	█	█	█		
NF2								
Cutaneous Schwann Cutaneous Schwann Vestibular Vestibular Vestibular Vestibular (EU Trial:UK) Vestibular (EU Trial:UK) Vestibular Vestibular, Meningioma	mTOR mAb anti-VEGF Antiangiogenic VEGF/PDGF mAb anti-VEGF Tyr-Kinase (BCR-Abl) Multi-kinase inhibitor EGFR-ErbB2 mTOR	RAD001 (everolimus) Bevacizumab (Avastin) Endostatin (YH-16) Axitinib Bevacizumab (Avastin) Nilotinib Sorafenib Lapatinib RAD001 (everolimus)	█	█	█	█		